Japan’s Ministry of Health, Labour and Welfare (MHLW) has recommended the approval of four new drugs, including Eli Lilly’s Zepbound (tirzepatide) for obesity and Biogen’s Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) with the superoxide dismutase 1 (SOD1) gene mutation.
New Japan Approval Recommendations Include Zepbound, Qalsody
A new batch of positive approval recommendations in Japan includes an ALS drug requested by a local patient group.
More from Japan
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.
• By
A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.
• By
Japan's MHLW has decided to tone down planned policy revisions that would have cut benefits under a patient support scheme for high-priced drugs, after resistance from patient groups.
More from Product Reviews
• By
Novartis is planning to file EU and US marketing applications for an intrathecal formulation of its spinal muscular atrophy gene therapy, Zolgensma, in H1 2025.
• By
Sponsors of three drugs that are in the final stages of the EU regulatory review cycle are due to make the case for marketing approval before the European Medicines Agency.
• By
The European Medicines Agency is this week set to issue an opinion on whether pan-EU marketing should be granted to Lilly’s Alzheimer’s disease drug donanemab.